China BTK Challenger Enters Western Markets

Summary InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients. What Happened The company showcased data across CLL, MCL, WM, MZL and DLBCL while highlighting the first Western patient experience with orelabrutinib.…